Literature DB >> 23420234

Optimal timing of coronary invasive strategy in non-ST-segment elevation acute coronary syndromes: a systematic review and meta-analysis.

Eliano P Navarese1, Paul A Gurbel2, Felicita Andreotti3, Udaya Tantry2, Young-Hoon Jeong2, Marek Kozinski1, Thomas Engstrøm4, Giuseppe Di Pasquale5, Waclaw Kochman6, Diego Ardissino7, Elvin Kedhi8, Gregg W Stone9, Jacek Kubica1.   

Abstract

BACKGROUND: The optimal timing of coronary intervention in patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACSs) is a matter of debate. Conflicting results among published studies partly relate to different risk profiles of the studied populations.
PURPOSE: To do the most comprehensive meta-analysis of current evidence on early versus delayed invasive treatment in NSTE-ACS. DATA SOURCES: MEDLINE, PubMed Central, and Google Scholar databases; conference proceedings; ClinicalTrials.gov registry; and Current Controlled Trials registry through May 2012. STUDY SELECTION: Available randomized, controlled trials (RCTs) and observational studies comparing early versus delayed intervention in the NSTE-ACS population. DATA EXTRACTION: Data were extracted for populations, interventions, outcomes, and risk of bias. All-cause mortality was the prespecified primary end point. The longest follow-up available in each study was chosen. The odds ratio with 95% CI was the effect measure. DATA SYNTHESIS: Seven RCTs (5370 patients) and 4 observational studies (77 499 patients) were included. Early intervention was less than 20 hours after hospitalization or randomization for RCTs and 24 hours or less for observational studies. Meta-analysis of the RCTs was inconclusive for a survival benefit associated with the early invasive strategy (odds ratio, 0.83 [95% CI, 0.64 to 1.09]; P = 0.180); a similar result emerged from the observational studies. With early versus late intervention, the odds ratios in the RCTs were 1.15 (CI, 0.65 to 2.01; P = 0.63) and 0.76 (CI, 0.56 to 1.04; P = 0.090) for myocardial infarction and major bleeding during follow-up, respectively. LIMITATION: Current evidence from RCTs is limited by the small overall sample size, low numbers of events in some trials, and heterogeneity in the timing of intervention and in patient risk profiles.
CONCLUSION: At present, there is insufficient evidence either in favor of or against an early invasive approach in the NSTE-ACS population. A more definitive RCT is warranted to guide clinical practice.

Entities:  

Mesh:

Year:  2013        PMID: 23420234     DOI: 10.7326/0003-4819-158-4-201302190-00006

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  37 in total

1.  [ESC guidelines 2015. Non-ST-elevation acute coronary syndrome].

Authors:  A Jobs; H Thiele
Journal:  Herz       Date:  2015-12       Impact factor: 1.443

2.  Response to Lascarrou et al.: Coronary angiography after cardiac arrest: useful for whom?

Authors:  Josef Dankiewicz; Jesper Kjaergaard; Hans Friberg
Journal:  Intensive Care Med       Date:  2015-06-16       Impact factor: 17.440

3.  Survival in patients without acute ST elevation after cardiac arrest and association with early coronary angiography: a post hoc analysis from the TTM trial.

Authors:  J Dankiewicz; N Nielsen; M Annborn; T Cronberg; D Erlinge; Y Gasche; C Hassager; J Kjaergaard; T Pellis; H Friberg
Journal:  Intensive Care Med       Date:  2015-03-24       Impact factor: 17.440

4.  Out-of-Hospital Cardiac Arrest in Acute Myocardial Infarction and STEMI Networks.

Authors:  Theodora Benedek; Mariann Gyöngyösi
Journal:  J Crit Care Med (Targu Mures)       Date:  2016-02-09

5.  Prime time for the sweet spot in timing of coronary invasive approach in patients with non-ST elevation myocardial infarction.

Authors:  Eliano P Navarese; Bernhard Wernly; Michael Lichtenauer; Martino Pepe; Wojciech Wanha; Giuseppe Ferrante; Lara Frediani; Verena Veulemans; Tobias Zeus; Ralf Westenfeld; Christian Jung; Paul A Gurbel
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

6.  Timing of invasive strategy in patients with non-ST-segment elevation acute coronary syndrome and effect on clinical outcomes.

Authors:  Vladan Vukcevic; Goran Stankovic
Journal:  J Thorac Dis       Date:  2017-11       Impact factor: 2.895

7.  Early versus delayed invasive strategy for intermediate- and high-risk acute coronary syndromes managed without P2Y12 receptor inhibitor pretreatment: Design and rationale of the EARLY randomized trial.

Authors:  Gilles Lemesle; Marc Laine; Mathieu Pankert; Etienne Puymirat; Thomas Cuisset; Ziad Boueri; Luc Maillard; Sébastien Armero; Guillaume Cayla; Laurent Bali; Pascal Motreff; Jean-Pascal Peyre; Franck Paganelli; François Kerbaul; Antoine Roch; Pierre Michelet; Karine Baumstarck; Laurent Bonello
Journal:  Clin Cardiol       Date:  2018-01-22       Impact factor: 2.882

Review 8.  After COACT trial-new perspectives for the management of non-ST elevation myocardial infarction: early versus late cardiac catheterization post cardiac arrest.

Authors:  Miguel A Maturana; Charles F Clinton; Selene Caballero-Cummings; Brandon Cave; Amal Khan; Amit Nanda; Devarshi Ardeshna; Joel Raja; Rami N Khouzam
Journal:  Ann Transl Med       Date:  2019-09

9.  Early surgical myocardial revascularization in non-ST-segment elevation acute coronary syndrome.

Authors:  Sebastian V Rojas; Mai Linh Trinh-Adams; Aitor Uribarri; Felix Fleissner; Pavel Iablonskii; Sara Rojas-Hernandez; Marcel Ricklefs; Andreas Martens; Stefan Rümke; Gregor Warnecke; Serghei Cebotari; Axel Haverich; Issam Ismail
Journal:  J Thorac Dis       Date:  2019-11       Impact factor: 2.895

10.  Prognostic benefit from an early invasive strategy in patients with non-ST elevation acute coronary syndrome (NSTEACS): evaluation of the new risk stratification in the NSTEACS European guidelines.

Authors:  Jesús Martinón-Martínez; Belén Álvarez Álvarez; Teba González Ferrero; Federico García-Rodeja Arias; Óscar Otero García; Carla Cacho Antonio; Charigan Abou Jokh Casas; Pilar Zuazola; Alberto Cordero; David Escribano; Belén Cid Alvarez; Diego Iglesias Álvarez; Rosa Agra Bermejo; Pedro Rigueiro Veloso; José María García Acuña; Francisco Gude Sampedro; José Ramón González Juanatey
Journal:  Clin Res Cardiol       Date:  2021-03-09       Impact factor: 5.460

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.